Your browser doesn't support javascript.
A Proposed Brain-, Spine-, and Mental- Health Screening Methodology (NEUROSCREEN) for Healthcare Systems: Position of the Society for Brain Mapping and Therapeutics.
Nami, Mohammad; Thatcher, Robert; Kashou, Nasser; Lopes, Dahabada; Lobo, Maria; Bolanos, Joe F; Morris, Kevin; Sadri, Melody; Bustos, Teshia; Sanchez, Gilberto E; Mohd-Yusof, Alena; Fiallos, John; Dye, Justin; Guo, Xiaofan; Peatfield, Nicholas; Asiryan, Milena; Mayuku-Dore, Alero; Krakauskaite, Solventa; Soler, Ernesto Palmero; Cramer, Steven C; Besio, Walter G; Berenyi, Antal; Tripathi, Manjari; Hagedorn, David; Ingemanson, Morgan; Gombosev, Marinela; Liker, Mark; Salimpour, Yousef; Mortazavi, Martin; Braverman, Eric; Prichep, Leslie S; Chopra, Deepak; Eliashiv, Dawn S; Hariri, Robert; Tiwari, Ambooj; Green, Ken; Cormier, Jason; Hussain, Namath; Tarhan, Nevzat; Sipple, Daniel; Roy, Michael; Yu, John S; Filler, Aaron; Chen, Mike; Wheeler, Chris; Ashford, J Wesson; Blum, Kenneth; Zelinsky, Deborah; Yamamoto, Vicky; Kateb, Babak.
  • Nami M; Society for Brain Mapping and Therapeutics (SBMT), Los Angeles, CA, USA.
  • Thatcher R; Brain Mapping Foundation (BMF), Los Angeles, CA, USA.
  • Kashou N; Neuroscience Center, Instituto de Investigaciones Científicas y Servicios de Alta Tecnología (INDICASAT AIP), City of Knowledge, Panama.
  • Lopes D; Department of Neuroscience, School of Advanced Medical Sciences and Technologies, and Dana Brain Health Institute, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Lobo M; Inclusive Brain Health and BrainLabs International, Swiss Alternative Medicine, Geneva, Switzerland.
  • Bolanos JF; Society for Brain Mapping and Therapeutics (SBMT), Los Angeles, CA, USA.
  • Morris K; Applied Neuroscience, Inc., St Petersburg, FL, USA.
  • Sadri M; Society for Brain Mapping and Therapeutics (SBMT), Los Angeles, CA, USA.
  • Bustos T; Brain Mapping Foundation (BMF), Los Angeles, CA, USA.
  • Sanchez GE; Society for Brain Mapping and Therapeutics (SBMT), Los Angeles, CA, USA.
  • Mohd-Yusof A; Brain Mapping Foundation (BMF), Los Angeles, CA, USA.
  • Fiallos J; Society for Brain Mapping and Therapeutics (SBMT), Los Angeles, CA, USA.
  • Dye J; Brain Mapping Foundation (BMF), Los Angeles, CA, USA.
  • Guo X; Society for Brain Mapping and Therapeutics (SBMT), Los Angeles, CA, USA.
  • Peatfield N; Brain Mapping Foundation (BMF), Los Angeles, CA, USA.
  • Asiryan M; Society for Brain Mapping and Therapeutics (SBMT), Los Angeles, CA, USA.
  • Mayuku-Dore A; Brain Mapping Foundation (BMF), Los Angeles, CA, USA.
  • Krakauskaite S; Society for Brain Mapping and Therapeutics (SBMT), Los Angeles, CA, USA.
  • Soler EP; Brain Mapping Foundation (BMF), Los Angeles, CA, USA.
  • Cramer SC; Society for Brain Mapping and Therapeutics (SBMT), Los Angeles, CA, USA.
  • Besio WG; Brain Mapping Foundation (BMF), Los Angeles, CA, USA.
  • Berenyi A; Society for Brain Mapping and Therapeutics (SBMT), Los Angeles, CA, USA.
  • Tripathi M; Brain Mapping Foundation (BMF), Los Angeles, CA, USA.
  • Hagedorn D; Society for Brain Mapping and Therapeutics (SBMT), Los Angeles, CA, USA.
  • Ingemanson M; Brain Mapping Foundation (BMF), Los Angeles, CA, USA.
  • Gombosev M; Society for Brain Mapping and Therapeutics (SBMT), Los Angeles, CA, USA.
  • Liker M; Brain Mapping Foundation (BMF), Los Angeles, CA, USA.
  • Salimpour Y; Department of Neurosurgery, Loma Linda University, Loma Linda, CA, USA.
  • Mortazavi M; Department of Neurology, Loma Linda University, CA, USA.
  • Braverman E; Protome Technologies Inc., Vancouver, Canada.
  • Prichep LS; Society for Brain Mapping and Therapeutics (SBMT), Los Angeles, CA, USA.
  • Chopra D; Brain Mapping Foundation (BMF), Los Angeles, CA, USA.
  • Eliashiv DS; Society for Brain Mapping and Therapeutics (SBMT), Los Angeles, CA, USA.
  • Hariri R; Brain Mapping Foundation (BMF), Los Angeles, CA, USA.
  • Tiwari A; Society for Brain Mapping and Therapeutics (SBMT), Los Angeles, CA, USA.
  • Green K; Brain Mapping Foundation (BMF), Los Angeles, CA, USA.
  • Cormier J; Society for Brain Mapping and Therapeutics (SBMT), Los Angeles, CA, USA.
  • Hussain N; Brain Mapping Foundation (BMF), Los Angeles, CA, USA.
  • Tarhan N; Department of Neurology, UCLA, and California Rehabilitation Institute, Los Angeles, CA, USA.
  • Sipple D; Electrical Computer and Biomedical Engineering Department and Interdisciplinary Neuroscience Program, University of Rhode Island, RI, USA.
  • Roy M; The Neuroscience Institute, New York University, New York, NY, USA.
  • Yu JS; Department of Neurology, All India Institute of Medical Sciences, New Delhi, India.
  • Filler A; Evoke Neuroscience, New York, NY, USA.
  • Chen M; Evoke Neuroscience, New York, NY, USA.
  • Wheeler C; SPARK Neuroscience, New York, NY, USA.
  • Ashford JW; Department of Neurosurgery, Children's Hospital Los Angeles, Los Angeles, CA, USA.
  • Blum K; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Zelinsky D; California Institute of Neuroscience, Thousand Oaks, CA, USA.
  • Yamamoto V; PATH Foundation NY, New York, NY, USA.
  • Kateb B; BrainScope Inc., Bethesda, MD, USA.
J Alzheimers Dis ; 86(1): 21-42, 2022.
Article in English | MEDLINE | ID: covidwho-1736733
ABSTRACT
The COVID-19 pandemic has accelerated neurological, mental health disorders, and neurocognitive issues. However, there is a lack of inexpensive and efficient brain evaluation and screening systems. As a result, a considerable fraction of patients with neurocognitive or psychobehavioral predicaments either do not get timely diagnosed or fail to receive personalized treatment plans. This is especially true in the elderly populations, wherein only 16% of seniors say they receive regular cognitive evaluations. Therefore, there is a great need for development of an optimized clinical brain screening workflow methodology like what is already in existence for prostate and breast exams. Such a methodology should be designed to facilitate objective early detection and cost-effective treatment of such disorders. In this paper we have reviewed the existing clinical protocols, recent technological advances and suggested reliable clinical workflows for brain screening. Such protocols range from questionnaires and smartphone apps to multi-modality brain mapping and advanced imaging where applicable. To that end, the Society for Brain Mapping and Therapeutics (SBMT) proposes the Brain, Spine and Mental Health Screening (NEUROSCREEN) as a multi-faceted approach. Beside other assessment tools, NEUROSCREEN employs smartphone guided cognitive assessments and quantitative electroencephalography (qEEG) as well as potential genetic testing for cognitive decline risk as inexpensive and effective screening tools to facilitate objective diagnosis, monitor disease progression, and guide personalized treatment interventions. Operationalizing NEUROSCREEN is expected to result in reduced healthcare costs and improving quality of life at national and later, global scales.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pandemics / COVID-19 Type of study: Diagnostic study / Clinical Practice Guide / Qualitative research / Screening study Limits: Aged / Humans / Male Language: English Journal: J Alzheimers Dis Journal subject: Geriatrics / Neurology Year: 2022 Document Type: Article Affiliation country: JAD-215240

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pandemics / COVID-19 Type of study: Diagnostic study / Clinical Practice Guide / Qualitative research / Screening study Limits: Aged / Humans / Male Language: English Journal: J Alzheimers Dis Journal subject: Geriatrics / Neurology Year: 2022 Document Type: Article Affiliation country: JAD-215240